Sangamo and new gene therapy partner Pfizer lifted by FDA fast track – pharmaphorum
pharmaphorum |
Sangamo and new gene therapy partner Pfizer lifted by FDA fast track
pharmaphorum Sangamo Therapeutics has been granted a fast track designation from the FDA for SB-525, its gene therapy candidate for haemophilia A. It was just a week ago that Pfizer announced it had acquired the rights to haemophilia gene therapy programmes being … FDA to fast-track Pfizer/Sangamo gene therapy orphan drug |
